tepotinib,osimertinib
merck,astrazeneca
['lung', 'insight 2', 'osimertinib', 'lcsm,(-blcsm)', 'tepotinib', 'rs onco']
#esmo22 news: initial insight 2 data reported by ( ) - point to activity of tepotinib plus osimertinib in egfr-mutated advanced non-small-cell lung cancer with acquired met amplification #lcsm 
Medicine Matters #oncology publishes the latest news, commentary, research, and educational resources in a range of topics across oncology.